Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • USFDA approves...

    USFDA approves Aurobindo Pharma Famotidine Drug for Heartburn and Pain Relief

    Written by savita thakur thakur Published On 2016-04-28T11:35:56+05:30  |  Updated On 28 April 2016 11:35 AM IST

    New Delhi : Aurobindo Pharma said it has received final approval from the US health regulator to manufacture and market generic version of heartburn relief medicine Famotidine tablets.


    The approval by the US Food and Drug Administration (USFDA) is for strengths of 10 mg and 20 mg, the company said in a BSE filing.

    This product is expected to be launched in the second quarter of 2016-17, it added.

    The drug is bio-equivalent and therapeutically equivalent to the reference listed product Pepcid AC Tablets 10 mg and 20 mg of McNeil Consumer Pharmaceuticals Co, it said.

    Citing IMS data, the company said that the approved product had an estimated market size of USD 31 million in the 12 month period ended February 2016.

    Aurobindo Pharma also received final approval from the USFDA to manufacture and market pain relief drug Oxymorphone Hydrochloride tablets in the strengths of 5 mg and 10 mg.

    "The approved ANDA is bio-equivalent and therapeutically equivalent to the reference listed drug product Opana (Oxymorphone Hydrochloride) tablets, 5 mg and 10 mg, of Endo Pharmaceuticals, Inc," it added.

    Oxymorphone Hydrochloride tablets is used to help relieve moderate to severe acute pain where the use of an opioid is appropriate.

    The approved product has an estimated market size of USD 55.5 million for the twelve months ending February 2016 according to IMS.

    Aurobindo now has a total of 257 ANDA approvals (220 final approvals including 10 from Aurolife Pharma LLC and 37 tentative approvals) from the USFDA.

    Shares of the company were trading 0.10 per cent down at Rs 774.65 apiece on BSE.
    Aurobindo PharmaFamotidineHeartburn drugMcNeil Consumer Pharmaceuticals CoOxymorphone HydrochloridePain relief DrugUS Food & Drug AdministrationUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok